Author/Authors :
Bonanno, Elena Department of Experimental Medicine - University of Rome “Tor Vergata” - Via Montpellier - Rome, Italy , Toschi, Nicola Department of Biomedicine and Prevention - University of Rome “Tor Vergata” - Via Montpellier - Rome, Italy , Bombonati, Alessandro Department of Pathology and Laboratory Medicine - Einstein Medical Center - Philadelphia, USA , Muto, Pietro Istituto Nazionale Tumori-IRCCS-G. Pascale Foundation - Naples, Italy , Schillaci, Orazio Department of Biomedicine and Prevention - University of Rome “Tor Vergata” - Via Montpellier - Rome, Italy
Abstract :
Personalized medicine is one of the main objectives of both
basic and translational cancer research. Nevertheless, it has
become clear that the creation of personalized therapeutic
protocols requires synergistic, transdisciplinary competencies. Indeed, novel approved therapies rarely take into
account both the interindividual variability and the aptitude of cancer cells to undergo those genetic and molecular adaptation involved in the drug resistance
phenomenon. In spite of recent and promising biomedical
and biomarker discoveries, individually tailored medical
care is still far from reality, and molecules which are output
by preclinical trials are very rarely translatable to evaluation for the diagnostic or therapeutical potential.
